Drugs / Recombinant Zoster Vaccine
Recombinant Zoster Vaccine
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05718037 | Aug 2023 → Jan 2024 | herpes zoster | Wuhan BravoVax Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07614412 | Jan 2027 → Jan 2028 expected | type 1 diabetes mellitus | Ministry of Health, Saudi Arabia | Not yet recruiting | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT07502560 | Mar 2026 → Apr 2030 expected | herpes zoster | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 4 | NCT07280741 | Dec 2025 → Jul 2027 expected | rheumatic disorder | University of Sao Paulo General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06162494 | Mar 2024 → Mar 2027 expected | varicella zoster infection | Ann & Robert H Lurie Children's Hospital of Chicago | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05575830 | Dec 2022 → Apr 2025 overdue | — | Calmy Alexandra | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05596526 | Dec 2022 → Dec 2024 | herpes zoster | Prof Patrice Lalive | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04516408 | Apr 2021 → Sep 2023 | herpes zoster, systemic lupus erythematosus | RenJi Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07354659 Comparator | Jan 2026 → Mar 2027 expected | herpes zoster | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
Press releases naming this drug 24 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant zoster vaccine | “Recombinant Zoster Vaccine (CHO cell)，two-dose vaccination schedule (Month 0, 2)” NCT07354659 ↗ |
| Known as | RZV | “Recombinant zoster vaccine (RZV) is indicated for prevention of herpes zoster in adults aged ≥ 50 years old.” NCT04516408 ↗3“two doses of the adjuvanted recombinant Zoster vaccine (RZV, or Shingrix®)” NCT05596526 ↗ “Intervention 1: Recombinant Zoster Vaccine (Shingrix; RZV)” NCT07614412 ↗ “Recombinant Zoster Vaccine (RZV)” NCT07280741 ↗ |
| Known as | Shingrix | “all participants will receive 2 doses of recombinant zoster vaccine (Shingrix)” NCT06162494 ↗1“Intervention 1: Recombinant Zoster Vaccine (Shingrix; RZV)” NCT07614412 ↗ |
| Modality | Vaccine | “Recombinant zoster vaccine (RZV) is indicated for prevention of herpes zoster in adults aged ≥ 50 years old.” NCT04516408 ↗ |
| Route | Intramuscular | “Participants received two intramuscular doses of the vaccine 2 months apart.” NCT04516408 ↗ |